Pfizer COVID-19 pill gets FDA authorization
FDA’s authorized Paxlovid for patients of 12 years of age and older, weighing at least 88 pounds, with mild to moderate COVID-19 who are expected to be hospitalized or not survive
By Arghyadeep Dutta
Published - Dec 22, 2021, 09:20 PM ET
Last Updated - Feb 12, 2024, 02:41 PM EST
• FDA’s authorized Paxlovid for patients of 12 years of age and older, weighing at least 88 pounds, with mild to moderate COVID-19 who are expected to be hospitalized or not survive
• Pfizer raised its production estimates to 120 million courses of treatment from 80 million in 2022
Pfizer Inc on Wednesday announced that the U.S. Food and Drug Administration (FDA) authorized its oral antiviral pill for COVID-19, making it the first at-home treatment for the coronavirus.
Pfizer’s clinical trial data showed its antiviral regimen has an efficacy rate of 89% in preventing hospitalizations and deaths among high-risk patients with severe illnesses.
